FR2991874A1 - Composition, useful as hair cosmetic composition e.g. hair care lotion for treating human keratinous materials such as hair and/or scalp, comprises pyridine dicarboxylic acid ester, and vitamin B and/or its analogs or derivatives - Google Patents
Composition, useful as hair cosmetic composition e.g. hair care lotion for treating human keratinous materials such as hair and/or scalp, comprises pyridine dicarboxylic acid ester, and vitamin B and/or its analogs or derivatives Download PDFInfo
- Publication number
- FR2991874A1 FR2991874A1 FR1255610A FR1255610A FR2991874A1 FR 2991874 A1 FR2991874 A1 FR 2991874A1 FR 1255610 A FR1255610 A FR 1255610A FR 1255610 A FR1255610 A FR 1255610A FR 2991874 A1 FR2991874 A1 FR 2991874A1
- Authority
- FR
- France
- Prior art keywords
- vitamin
- hair
- composition
- composition according
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- -1 pyridine dicarboxylic acid ester Chemical class 0.000 title claims abstract description 35
- 235000019156 vitamin B Nutrition 0.000 title claims abstract description 17
- 239000011720 vitamin B Substances 0.000 title claims abstract description 17
- 229930003270 Vitamin B Natural products 0.000 title claims abstract description 16
- 210000004209 hair Anatomy 0.000 title claims description 41
- 239000002537 cosmetic Substances 0.000 title claims description 23
- 210000004761 scalp Anatomy 0.000 title claims description 17
- 239000006210 lotion Substances 0.000 title claims description 9
- 239000000463 material Substances 0.000 title claims description 8
- GJAWHXHKYYXBSV-UHFFFAOYSA-N pyridinedicarboxylic acid Natural products OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 title abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 9
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000001424 substituent group Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 23
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 10
- 102000011782 Keratins Human genes 0.000 claims description 9
- 108010076876 Keratins Proteins 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 229960003512 nicotinic acid Drugs 0.000 claims description 8
- 235000019160 vitamin B3 Nutrition 0.000 claims description 8
- 239000011708 vitamin B3 Substances 0.000 claims description 8
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 7
- 229960002079 calcium pantothenate Drugs 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 6
- 229930003537 Vitamin B3 Natural products 0.000 claims description 6
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 6
- 239000000835 fiber Substances 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- 239000004215 Carbon black (E152) Substances 0.000 claims description 5
- 229930003571 Vitamin B5 Natural products 0.000 claims description 5
- 125000001931 aliphatic group Chemical group 0.000 claims description 5
- 150000005840 aryl radicals Chemical class 0.000 claims description 5
- 229930195733 hydrocarbon Natural products 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 239000011675 vitamin B5 Substances 0.000 claims description 5
- 235000009492 vitamin B5 Nutrition 0.000 claims description 5
- 125000006702 (C1-C18) alkyl group Chemical group 0.000 claims description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 4
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 235000019161 pantothenic acid Nutrition 0.000 claims description 4
- 239000011713 pantothenic acid Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 4
- 229960002477 riboflavin Drugs 0.000 claims description 4
- 239000002453 shampoo Substances 0.000 claims description 4
- 229960003495 thiamine Drugs 0.000 claims description 4
- 235000019158 vitamin B6 Nutrition 0.000 claims description 4
- 239000011726 vitamin B6 Substances 0.000 claims description 4
- 235000021468 vitamin B8 Nutrition 0.000 claims description 4
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 claims description 3
- IFYVAPPYWOMVDP-ZDUSSCGKSA-N 3-[[(2r)-2,4-diacetyloxy-3,3-dimethylbutanoyl]amino]propyl acetate Chemical compound CC(=O)OCCCNC(=O)[C@H](OC(C)=O)C(C)(C)COC(C)=O IFYVAPPYWOMVDP-ZDUSSCGKSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- GMBVYJOWNGZGMU-NSHDSACASA-N [(3r)-4-(3-ethoxypropylamino)-3-hydroxy-2,2-dimethyl-4-oxobutyl] acetate Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)COC(C)=O GMBVYJOWNGZGMU-NSHDSACASA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 229940101267 panthenol Drugs 0.000 claims description 3
- 229940023735 panthenyl ethyl ether Drugs 0.000 claims description 3
- 229940114156 panthenyl ethyl ether acetate Drugs 0.000 claims description 3
- 235000020957 pantothenol Nutrition 0.000 claims description 3
- 239000011619 pantothenol Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 2
- 229930003451 Vitamin B1 Natural products 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 229930003471 Vitamin B2 Natural products 0.000 claims description 2
- 229930003756 Vitamin B7 Natural products 0.000 claims description 2
- 229930003761 Vitamin B9 Natural products 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 229960005069 calcium Drugs 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 2
- 239000011666 cyanocobalamin Substances 0.000 claims description 2
- 229960002104 cyanocobalamin Drugs 0.000 claims description 2
- LIVYVINPLCASPD-UHFFFAOYSA-N diethyl pyridine-2,3-dicarboxylate Chemical compound CCOC(=O)C1=CC=CN=C1C(=O)OCC LIVYVINPLCASPD-UHFFFAOYSA-N 0.000 claims description 2
- AFWWHZBUQWEDLS-UHFFFAOYSA-N diethyl pyridine-2,5-dicarboxylate Chemical compound CCOC(=O)C1=CC=C(C(=O)OCC)N=C1 AFWWHZBUQWEDLS-UHFFFAOYSA-N 0.000 claims description 2
- TUGSJNQAIMFEDY-UHFFFAOYSA-N dimethyl pyridine-2,5-dicarboxylate Chemical compound COC(=O)C1=CC=C(C(=O)OC)N=C1 TUGSJNQAIMFEDY-UHFFFAOYSA-N 0.000 claims description 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000005187 foaming Methods 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 235000005152 nicotinamide Nutrition 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 229940014662 pantothenate Drugs 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 235000008160 pyridoxine Nutrition 0.000 claims description 2
- 239000011677 pyridoxine Substances 0.000 claims description 2
- 239000002151 riboflavin Substances 0.000 claims description 2
- 235000019192 riboflavin Nutrition 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 235000019157 thiamine Nutrition 0.000 claims description 2
- 239000011721 thiamine Substances 0.000 claims description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 2
- 235000010374 vitamin B1 Nutrition 0.000 claims description 2
- 239000011691 vitamin B1 Substances 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019164 vitamin B2 Nutrition 0.000 claims description 2
- 239000011716 vitamin B2 Substances 0.000 claims description 2
- 235000011912 vitamin B7 Nutrition 0.000 claims description 2
- 239000011735 vitamin B7 Substances 0.000 claims description 2
- 235000019159 vitamin B9 Nutrition 0.000 claims description 2
- 239000011727 vitamin B9 Substances 0.000 claims description 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- YLKLGROVCSMPTK-UHFFFAOYSA-N bis(acetyloxymethyl) pyridine-2,4-dicarboxylate Chemical compound CC(=O)OCOC(=O)C1=CC=NC(C(=O)OCOC(C)=O)=C1 YLKLGROVCSMPTK-UHFFFAOYSA-N 0.000 claims 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 210000000720 eyelash Anatomy 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- MUUDQLHCIAOWPR-UHFFFAOYSA-N diethyl pyridine-2,4-dicarboxylate Chemical compound CCOC(=O)C1=CC=NC(C(=O)OCC)=C1 MUUDQLHCIAOWPR-UHFFFAOYSA-N 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 239000007957 coemulsifier Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229950001046 piroctone Drugs 0.000 description 2
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- UHGGERUQGSJHKR-VCDGYCQFSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;octadecanoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCCCCCCCCCCCC(O)=O UHGGERUQGSJHKR-VCDGYCQFSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- YTKGAYFHUZTLCI-UHFFFAOYSA-N 3-hydroxy-2-iminopyrimidin-4-amine Chemical compound NC1=CC=NC(=N)N1O YTKGAYFHUZTLCI-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- TVZCRIROJQEVOT-CABCVRRESA-N Cromakalim Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C#N)CCCC1=O TVZCRIROJQEVOT-CABCVRRESA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- FCKLFGKATYPJPG-SSTBVEFVSA-N Oxendolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1C[C@H](CC)[C@H](O)[C@@]1(C)CC2 FCKLFGKATYPJPG-SSTBVEFVSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000000471 Prostaglandin F receptors Human genes 0.000 description 1
- 108050008995 Prostaglandin F receptors Proteins 0.000 description 1
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 1
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- YQAHABBBFVAGBK-UHFFFAOYSA-N acetic acid;hexadecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCCCC(O)=O YQAHABBBFVAGBK-UHFFFAOYSA-N 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical class [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 229960002470 bimatoprost Drugs 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000003152 bradykinin antagonist Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229950004210 cromakalim Drugs 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- YLGIBCYHQZTFQL-UHFFFAOYSA-N dimethyl pyridine-2,3-dicarboxylate Chemical compound COC(=O)C1=CC=CN=C1C(=O)OC YLGIBCYHQZTFQL-UHFFFAOYSA-N 0.000 description 1
- TVKOFNSTLWFQHY-UHFFFAOYSA-N dimethyl pyridine-2,4-dicarboxylate Chemical compound COC(=O)C1=CC=NC(C(=O)OC)=C1 TVKOFNSTLWFQHY-UHFFFAOYSA-N 0.000 description 1
- FABZWGJHPAISRN-UHFFFAOYSA-N dipropan-2-yl pyridine-2,4-dicarboxylate Chemical compound CC(C)OC(=O)C1=CC=NC(C(=O)OC(C)C)=C1 FABZWGJHPAISRN-UHFFFAOYSA-N 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- RVYGVBZGSFLJKH-UHFFFAOYSA-N hexyl pyridine-3-carboxylate Chemical class CCCCCCOC(=O)C1=CC=CN=C1 RVYGVBZGSFLJKH-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical class C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229950006827 oxendolone Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 229940119519 peg-32 stearate Drugs 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940057874 phenyl trimethicone Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 125000003748 selenium group Chemical class *[Se]* 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229960002304 thenalidine Drugs 0.000 description 1
- KLOHYVOVXOUKQI-UHFFFAOYSA-N thenalidine Chemical compound C1CN(C)CCC1N(C=1C=CC=CC=1)CC1=CC=CS1 KLOHYVOVXOUKQI-UHFFFAOYSA-N 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004317 unoprostone Drugs 0.000 description 1
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
La présente invention concerne une composition cosmétique ou pharmaceutique comprenant au moins un dérivé d'acide pyridine-dicarboxylique en association avec au moins une vitamine B ou un de ses analogues, ainsi que son utilisation notamment dans le domaine capillaire.The present invention relates to a cosmetic or pharmaceutical composition comprising at least one pyridine-dicarboxylic acid derivative in combination with at least one vitamin B or one of its analogues, as well as its use in particular in the hair field.
La croissance des cheveux et leur renouvellement sont principalement déterminés par l'activité des follicules pileux et leur environnement matriciel. Leur activité est cyclique et comporte essentiellement trois phases à savoir la phase anagène, la phase catagène et la phase télogène. La chevelure se renouvelle en permanence et sur les 150 000 cheveux environ que comporte une chevelure, 10% environ sont au repos et seront remplacés dans les mois qui viennent. La chute ou perte naturelle des cheveux peut être estimée, en moyenne, à quelques cent cheveux par jour pour un état physiologique normal. Ce processus de renouvellement physique permanent subit une évolution naturelle au cours du vieillissement, les cheveux deviennent plus fins et leurs cycles plus courts. Il est connu, par ailleurs, que certains facteurs tels qu'un déséquilibre hormonal, un stress physiologique, la malnutrition, peuvent accentuer le phénomène. En outre, la chute ou l'altération des cheveux peut être en relation avec des phénomènes saisonniers.Hair growth and renewal are mainly determined by the activity of hair follicles and their matrix environment. Their activity is cyclic and comprises essentially three phases, namely the anagen phase, the catagen phase and the telogen phase. The hair is constantly renewed and about 150 000 hairs of hair, about 10% are at rest and will be replaced in the coming months. The fall or natural loss of hair can be estimated, on average, to a few hundred hairs a day for a normal physiological state. This process of permanent physical renewal undergoes a natural evolution during aging, the hair becomes thinner and their cycles shorter. It is known, moreover, that certain factors such as a hormonal imbalance, a physiological stress, the malnutrition, can accentuate the phenomenon. In addition, the fall or the alteration of the hair can be in relation with seasonal phenomena.
Il a ainsi notamment été proposé par le brevet EP1352629, d'utiliser des dérivés d'acide pyridine-dicarboxylique pour induire et/ou stimuler la croissance des fibres kératiniques humaines telles que les cheveux ou les cils, et/ou freiner leur chute et/ou augmenter leur densité.It has thus been proposed in particular by the patent EP1352629, to use pyridine-dicarboxylic acid derivatives to induce and / or stimulate the growth of human keratin fibers such as the hair or the eyelashes, and / or to slow down their fall and / or or increase their density.
Toutefois, on a constaté que l'utilisation de tels composés, particulièrement en présence de solvant, pouvait entraîner des sensations d'inconfort du cuir chevelu, telles que des tiraillements, ou encore des problèmes de sécheresse. Dans certains cas, on a également observé des cheveux ternes, sans tonus, ou difficiles à coiffer et à discipliner. La présente invention a notamment pour but de pallier ces inconvénients en proposant une composition permettant d'obtenir un effet bénéfique le plus étendu possible, ladite composition agissant de manière large sur le cuir chevelu et l'ensemble de la chevelure, du bulbe du cheveu à sa pointe. Grâce à l'invention, on peut ainsi obtenir d'une part l'effet technique lié à l'utilisation des dérivés d'acide pyridine-dicarboxylique, tout en ayant un bon effet cosmétique sur l'ensemble de la chevelure.However, it has been found that the use of such compounds, particularly in the presence of a solvent, can cause sensations of discomfort of the scalp, such as tightness, or even problems of dryness. In some cases, dull hair has also been observed, without tone, or difficult to comb and discipline. The present invention is intended in particular to overcome these drawbacks by proposing a composition making it possible to obtain the widest possible beneficial effect, said composition acting in a broad manner on the scalp and all of the hair, from the bulb of the hair to the his tip. Thanks to the invention, one can thus obtain on the one hand the technical effect related to the use of pyridine-dicarboxylic acid derivatives, while having a good cosmetic effect on the whole of the hair.
La présente invention a pour objet une composition comprenant : - (i) au moins un composé de formule générale (I), ou l'un de ses sels : COOR2 (I) COORi dans laquelle R1 et R2 représentent, indépendamment l'un de l'autre, un atome d'hydrogène, un radical hydrocarboné aliphatique en C1-C18, linéaire ou ramifié, saturé ou insaturé (alkyle notamment); ou un radical aryle en C6-C18; lesdits radicaux hydrocarboné aliphatique ou aryle étant éventuellement substitués par un ou plusieurs groupes choisis parmi OH, NH2, -OR, -OCOR et -NHR avec R représentant un groupement alkyle en C1-C18, l'un au moins des groupements R1 et R2 étant différent d'un atome d'hydrogène; et - (ii) au moins une vitamine B et/ou un de ses analogues ou dérivés. Un autre objet de l'invention concerne l'utilisation d'une composition ainsi définie pour induire et/ou stimuler la croissance des fibres kératiniques humaines et/ou freiner leur chute et/ou augmenter leur densité.The present invention relates to a composition comprising: - (i) at least one compound of general formula (I), or one of its salts: COOR 2 (I) COOR 1 in which R 1 and R 2 represent, independently of one of the other, a hydrogen atom, a linear or branched, saturated or unsaturated (alkyl) aliphatic hydrocarbon radical C1-C18; or a C6-C18 aryl radical; said aliphatic or aryl hydrocarbon radicals being optionally substituted by one or more groups selected from OH, NH2, -OR, -OCOR and -NHR with R representing a C1-C18 alkyl group, at least one of R1 and R2 being different from a hydrogen atom; and - (ii) at least one vitamin B and / or one of its analogues or derivatives. Another subject of the invention relates to the use of a composition thus defined for inducing and / or stimulating the growth of human keratinous fibers and / or slowing down their fall and / or increasing their density.
On a constaté que les compositions selon l'invention présentaient de bonnes performances cosmétiques, au niveau de la qualité des cheveux, et également au niveau du confort du cuir chevelu. Le cuir chevelu est apaisé, et aucun tiraillement ou échauffement n'est observé après l'application de la composition. La chevelure est disciplinée, facile à coiffer, les cheveux sont plus forts et plus résistants. Dans la présente description, l'expression "au moins un" est équivalente à l'expression "un ou plusieurs" et peut y être substituée; et l'expression "compris entre ... et ..." est équivalente à l'expression "allant de ... à ..." et peut y être 25 substituée. 1/ Ester d'acide pyridine dicarboxylique La composition selon l'invention comprend donc au moins un composé qui est un ester d'acide pyridine dicarboxylique. L'ester peut être un monoester ou un diester, 30 de préférence un diester. Il peut également s'agir d'un sel d'un tel ester. Lesdits composés répondent à la formule générale (I), ou l'un de ses sels : COOR2 (I) COORi 35 dans laquelle R1 et R2 représentent, indépendamment l'un de l'autre, un atome d'hydrogène, un radical hydrocarboné aliphatique en C1-C18, linéaire ou ramifié, saturé ou insaturé (alkyle notamment); ou un radical aryle en C6-C18; lesdits radicaux hydrocarboné aliphatique ou aryle étant éventuellement substitués par un ou plusieurs groupes choisis parmi OH, NH2, -OR, -OCOR et -NHR avec R représentant un groupement alkyle en C1-C18, l'un au moins des groupements R1 et R2 étant différent d'un atome d'hydrogène. De préférence, les substituants COORi et COOR2 sont respectivement en position 2 et 3, ou 2 et 4 du noyau pyridine. Préférentiellement, ils sont en position 2 et 4.It has been found that the compositions according to the invention have good cosmetic performances, in terms of the quality of the hair, and also in terms of the comfort of the scalp. The scalp is soothed, and no tugging or heating is observed after the application of the composition. The hair is disciplined, easy to comb, the hair is stronger and more resistant. In the present description, the term "at least one" is equivalent to the term "one or more" and may be substituted therefor; and the term "between ... and ..." is equivalent to the phrase "from ... to ..." and may be substituted therefor. 1 / Pyridine dicarboxylic acid ester The composition according to the invention therefore comprises at least one compound which is a pyridine dicarboxylic acid ester. The ester may be a monoester or a diester, preferably a diester. It can also be a salt of such an ester. Said compounds correspond to the general formula (I), or one of its salts: COOR 2 (I) COOR 1 in which R 1 and R 2 represent, independently of one another, a hydrogen atom, a hydrocarbon radical C1-C18 aliphatic, linear or branched, saturated or unsaturated (especially alkyl); or a C6-C18 aryl radical; said aliphatic or aryl hydrocarbon radicals being optionally substituted by one or more groups selected from OH, NH2, -OR, -OCOR and -NHR with R representing a C1-C18 alkyl group, at least one of R1 and R2 being different from a hydrogen atom. Preferably, the substituents COOR 1 and COOR 2 are respectively in position 2 and 3, or 2 and 4 of the pyridine ring. Preferably, they are in position 2 and 4.
Préférentiellement, les composés répondent à la formule (la), ou un de ses sels : COOR2 (la) COORi dans laquelle R1 et R2 représentent, indépendamment l'un de l'autre, un atome d'hydrogène, un radical hydrocarboné aliphatique en C1-C18, linéaire ou ramifié, saturé ou insaturé (alkyle notamment); ou un radical aryle en C6-C18; lesdits radicaux hydrocarboné aliphatique ou aryle étant éventuellement substitués par un ou plusieurs groupes choisis parmi OH, NH2, -OR, -OCOR et -NHR avec R représentant un groupement alkyle en C1-C18, l'un au moins des groupements R1 et R2 étant différent d'un atome d'hydrogène.Preferably, the compounds correspond to formula (Ia), or a salt thereof: COOR 2 (la) COOR 1 in which R 1 and R 2 represent, independently of one another, a hydrogen atom, an aliphatic hydrocarbon radical in C1-C18, linear or branched, saturated or unsaturated (especially alkyl); or a C6-C18 aryl radical; said aliphatic or aryl hydrocarbon radicals being optionally substituted by one or more groups selected from OH, NH2, -OR, -OCOR and -NHR with R representing a C1-C18 alkyl group, at least one of R1 and R2 being different from a hydrogen atom.
De préférence, dans les formules (I) et (la), le radical hydrocarboné aliphatique, notamment alkyle, en C1-C18 est un radical hydrocarboné aliphatique, notamment alkyle, en C1-C10, notamment en C1-C6, tel que méthyle, éthyle, tertiobutyle, isopropyle, hexyle. Ledit radical hydrocarboné aliphatique peut également contenir au moins une double liaison ou une triple liaison carbone-carbone, comme par exemple -CH=CH2, -CH2-CH=CH-CH3et -CH2-CECH. Le radical aryle peut représenter le radical phényle ou naphtyle. En particulier, dans les formules (I) et (la), R1 et R2 représentent, indépendam- ment l'un de l'autre, un atome d'hydrogène, un radical hydrocarboné aliphatique saturé, notamment alkyle, linéaire ou ramifié, en C1-C18, mieux en C1-C10, voire en C1-C6, éventuellement substitué par un groupe alcoxy ou acyloxy (OR ou OCOR avec R désignant un radical alkyle en C1-C18), l'un au moins des groupements R1 et R2 étant différent d'un atome d'hydrogène.Preferably, in the formulas (I) and (Ia), the aliphatic hydrocarbon radical, in particular C 1 -C 18 alkyl, is an aliphatic hydrocarbon radical, in particular C 1 -C 10 alkyl, especially C 1 -C 6, such as methyl, ethyl, tert-butyl, isopropyl, hexyl. Said aliphatic hydrocarbon radical may also contain at least one double bond or a carbon-carbon triple bond, for example -CH = CH2, -CH2-CH = CH-CH3 and -CH2-CECH. The aryl radical may represent the phenyl or naphthyl radical. In particular, in the formulas (I) and (Ia), R1 and R2 represent, independently of one another, a hydrogen atom, a saturated aliphatic hydrocarbon radical, in particular a linear or branched alkyl radical, C1-C18, more preferably C1-C10 or even C1-C6, optionally substituted with an alkoxy or acyloxy group (OR or OCOR with R denoting a C1-C18 alkyl radical), at least one of the groups R1 and R2 being different from a hydrogen atom.
De préférence, R1 et R2 sont identiques. Préférentiellement, R1 et R2 sont identiques et représentent un radical alkyl saturé et linéaire en C1-C18, de préférence en C1-C10, et encore mieux en C1-C6; et tout particulièrement un radical éthyle. On peut notamment utiliser les composés de formule (I) suivants : - le pyridine-2,4-dicarboxylate de diméthyle, - le pyridine-2,3-dicarboxylate de diméthyle, - le pyridine-2,4-dicarboxylate de diéthyle, - le pyridine-2,3-dicarboxylate de diéthyle, - le pyridine-2,5-dicarboxylate de diéthyle, - le pyridine-2,5-dicarboxylate de diméthyle, - le pyridine-2,4-dicarboxylate de diisopropyle, - le pyridine-2,4-dicarboxylate de di(acétyloxyméthyle) (dérivé de formule (I) tel que R1 et R2 représentent -CH2-0-COCH3), Préférentiellement, la composition comprend, comme composé de formule (I) ou (la), le pyridine-2,4-dicarboxylate de diéthyle. Par sels des composés de formule (I), on entend selon l'invention les sels organiques ou minéraux d'un composé de formule (I), ces sels étant physiologiquement acceptables. Comme sels minéraux, on peut citer les sels de sodium ou de potassium ainsi que les sels de zinc (Zn2+), de calcium (Ca2+), de cuivre (Cu2+), de fer (Fe2+), de strontium (Sr2+), de magnésium (Mg2+), de manganèse (Mn2+); les hydroxydes, les carbonates et les chlorures. Comme sels organiques, on peut citer les sels triéthanolamine, mono-éthanolamine, diéthanolamine, hexadécylamine, N,N,N',N'-tétrakis-(hydroxy-propy1-2) éthylène di-amine et tris-hydroxyméthyl aminométhane. Les composés de formule (I) sont connus en tant que tels; ils sont notamment décrits, ainsi que leur fabrication, dans le brevet EP1352629.Preferably, R1 and R2 are the same. Preferably, R1 and R2 are identical and represent a linear and saturated C1-C18, preferably C1-C10, and even more preferably C1-C6, alkyl radical; and most preferably an ethyl radical. The following compounds of formula (I) can especially be used: dimethyl pyridine-2,4-dicarboxylate, dimethyl pyridine-2,3-dicarboxylate, diethyl pyridine-2,4-dicarboxylate, diethyl pyridine-2,3-dicarboxylate, diethyl pyridine-2,5-dicarboxylate, dimethyl pyridine-2,5-dicarboxylate, diisopropyl pyridine-2,4-dicarboxylate, pyridine Di (acetyloxymethyl) -2,4-dicarboxylate (derivative of formula (I) such that R1 and R2 represent -CH2-O-COCH3), Preferably, the composition comprises, as compound of formula (I) or (la), pyridine-2,4-diethyl dicarboxylate. By salts of the compounds of formula (I) is meant according to the invention the organic or inorganic salts of a compound of formula (I), these salts being physiologically acceptable. As mineral salts, mention may be made of sodium or potassium salts as well as the salts of zinc (Zn2 +), calcium (Ca2 +), copper (Cu2 +), iron (Fe2 +), strontium (Sr2 +), magnesium (Mg 2+), manganese (Mn 2+); hydroxides, carbonates and chlorides. As organic salts, mention may be made of the triethanolamine, monoethanolamine, diethanolamine, hexadecylamine, N, N, N ', N'-tetrakis (hydroxypropyl) ethylene di-amine and tris-hydroxymethylaminomethane salts. The compounds of formula (I) are known as such; they are particularly described, as well as their manufacture, in patent EP1352629.
De préférence, la composition selon l'invention comprend le ou les composés de formule (I) en une quantité comprise entre 0,001 et 10% en poids, notamment de 0,01 à 5% poids, par rapport au poids total de la composition. 2/ Vitamine B La composition selon l'invention comprend également au moins une vitamine B et/ou un de leurs analogues ou dérivés. Par vitamine B, on entend au moins l'une des vitamines appartenant à ce groupe, à savoir : - la vitamine B1 ou thiamine; - la vitamine B2 ou riboflavine; - la vitamine B3 (ou vitamine PP) ou niacine ou niacinamide; - la vitamine B5 ou acide pantothénique; - la vitamine B6 ou pyridoxine; - la vitamine B8 (ou vitamine H) ou biotine; - la vitamine B9 ou acide folique, et - la vitamine B12 ou cyanocobalamine.Preferably, the composition according to the invention comprises the compound (s) of formula (I) in an amount of between 0.001 and 10% by weight, especially from 0.01 to 5% by weight, relative to the total weight of the composition. 2 / Vitamin B The composition according to the invention also comprises at least one vitamin B and / or one of their analogues or derivatives. Vitamin B means at least one of the vitamins belonging to this group, namely: vitamin B1 or thiamine; - vitamin B2 or riboflavin; vitamin B3 (or vitamin PP) or niacin or niacinamide; vitamin B5 or pantothenic acid; vitamin B6 or pyridoxine; - vitamin B8 (or vitamin H) or biotin; - vitamin B9 or folic acid, and - vitamin B12 or cyanocobalamin.
Comme analogues ou dérivés de vitamine B, on peut notamment citer les sels correspondants, comme le pantothénate de calcium, les pro-vitamines B comme le panthénol, qui est l'alcool analogue de la vitamine B5, encore appelé provitamine B5; on peut également citer les éthers et les esters correspondants, comme le panthényl éthyl éther, le panthényl éthyl éther acétate et le panthényl triacétate. On peut bien évidemment utiliser un mélange de ces différents composés. Préférentiellement, la vitamine B susceptible d'être employée dans le cadre de l'invention est choisie parmi la vitamine B3, la vitamine B5, la vitamine B6 et la vitamine B8, ou l'un de leurs analogues ou dérivés, et notamment le pantothénate de calcium, le panthénol, le panthényl éthyl éther, le panthényl éthyl éther acétate et le panthényl triacétate; ainsi que leurs mélanges.As analogues or derivatives of vitamin B, there may be mentioned the corresponding salts, such as calcium pantothenate, pro-vitamin B such as panthenol, which is the alcohol analog of vitamin B5, also called provitamin B5; mention may also be made of the corresponding ethers and esters, such as panthenyl ethyl ether, panthenyl ethyl ether acetate and panthenyl triacetate. It is of course possible to use a mixture of these different compounds. Preferably, the vitamin B that may be used in the context of the invention is chosen from vitamin B3, vitamin B5, vitamin B6 and vitamin B8, or one of their analogues or derivatives, and in particular pantothenate. calcium, panthenol, panthenyl ethyl ether, panthenyl ethyl ether acetate and panthenyl triacetate; as well as their mixtures.
De préférence, la composition selon l'invention comprend le ou les vitamines B ou analogues ou dérivés en une quantité comprise entre 0,001 et 5% en poids, notamment 0,005 et 2% en poids, encore mieux entre 0,01 et 1% en poids, par rapport au poids total de la composition. 3. Ingrédients complémentaires La composition selon l'invention peut être à usage cosmétique ou pharmaceutique. Préférentiellement, la composition selon l'invention est à usage cosmétique. Par "cosmétique", on entend au sens de l'invention une composition d'aspect, d'odeur et de toucher agréables. De préférence, la composition est d'application topique sur la peau et les fibres kératiniques, et plus spécialement sur le cuir che- velu, les cheveux et les cils. Selon le mode d'application, cette composition peut se présenter sous toutes les formes galéniques normalement utilisées dans le domaine considéré, notamment 35 cosmétique. Pour une application topique sur la peau, y compris le cuir chevelu, la composition peut avoir la forme notamment d'une solution ou suspension aqueuse, alcoolique ou hydroalcoolique, d'une suspension ou d'une solution huileuse, d'une émulsion 40 ou dispersion de consistance liquide ou semi-liquide obtenue par dispersion d'une phase grasse dans une phase aqueuse (HIE) ou inversement (E/H), d'une dispersion ou émulsion de consistance molle, d'un gel aqueux ou hydroalcoolique ou huileux (anhydre), d'une poudre libre ou compactée à utiliser telle quelle ou à in- corporer dans un milieu physiologiquement acceptable (excipient), ou encore de microcapsules ou microparticules, ou de dispersions vésiculaires de type ionique et/ou non ionique. On peut également envisager une composition sous la forme d'une mousse ou 5 encore sous forme de composition pour aérosol comprenant également un agent propulseur sous pression. En particulier, la composition selon l'invention peut être une composition capillaire, susceptible d'être appliquée sur le cuir chevelu ou les cheveux, et peut se présen- 10 ter sous forme d'une lotion de soin capillaire, par exemple d'application journalière ou bihebdomadaire, d'un shampooing ou d'un après-shampooing capillaire, en particulier d'application bihebdomadaire ou hebdomadaire, d'un savon liquide ou solide de nettoyage du cuir chevelu d'application journalière, d'un produit de mise en forme de la coiffure (laque, produit pour mise en pli, gel coiffant), d'un masque 15 traitant, d'une crème ou d'un gel moussant de nettoyage des cheveux. Elle peut encore se présenter sous forme de teinture ou de mascara capillaire à appliquer au pinceau ou au peigne. Pour une application sur les cils ou les poils, la composition selon l'invention peut se présenter sous forme d'un mascara, pigmenté ou non, à appliquer à la brosse 20 sur les cils ou encore sur les poils de barbe ou de moustache. Selon un mode de réalisation particulier, la composition selon l'invention se présente sous forme de crème ou lotion capillaire, de shampooing, d'après-shampooing capillaire, ou de mascara capillaire ou pour cils. 25 Les quantités des différents constituants de la composition selon l'invention sont celles classiquement utilisées dans les domaines considérés. En outre, cette composition est préparée selon les méthodes usuelles. Elle peut ainsi se présenter sous forme d'une lotion, sérum, lait, crème H/E ou E/H, gel, onguent, pommade, poudre, baume, patch, tampon imbibé, savon, pain, mousse. 30 Lorsque la composition est une émulsion, la proportion de la phase grasse peut aller de 2 à 80% en poids, de préférence de 5 à 50% en poids par rapport au poids total de la composition. La phase grasse peut contenir des composés gras ou huileux, liquides à tempéra- 35 ture ambiante (25°C) et pression atmosphérique (1 atm), généralement appelés huiles. Ces huiles peuvent être compatibles ou non entre elles et former une phase grasse liquide macroscopiquement homogène ou un système bi- ou triphasique. La phase grasse peut, en plus des huiles, contenir des cires, des gommes, des 40 polymères lipophiles, des produits "pâteux" ou visqueux contenant des parties so- lides et des parties liquides. La phase aqueuse est ajustée en fonction de la teneur en phase grasse et en composé(s) de formule (I) ainsi que de celle des éventuels ingrédients additionnels, pour obtenir 100% en poids. En pratique la phase aqueuse représente de préférence 5 à 99,9% en poids. La phase aqueuse contient de l'eau et éventuellement un solvant organique mis- cible en toute proportion à l'eau comme les alcools inférieurs en C1 à Cg tel que l'éthanol, l'isopropanol, les polyols comme le propylène glycol, le glycérol, le sorbitol ou encore l'acétone. Les émulsionnants et les coémulsionnants utilisés dans la composition sous forme d'émulsion peuvent être choisis parmi ceux classiquement utilisés dans le do- maine cosmétique ou pharmaceutique. L'émulsionnant et/ou le coémulsionnant sont de préférence présents dans la composition en une proportion allant de 0,1 à 30% en poids, de préférence de 0,5 à 20% en poids par rapport au poids total de la composition, mieux de 1 à 8%. Leur nature est, en outre, fonction du sens de l'émulsion. L'émulsion peut, en outre, comprendre des vésicules lipidiques et no- tamment des liposomes. Lorsque la composition est une solution ou un gel huileux, la phase grasse peut représenter plus de 90% du poids total de la composition. Avantageusement, pour une application capillaire, la composition est une solution ou suspension aqueuse, alcoolique ou hydroalcoolique, et mieux une solution ou une suspension eau/éthanol. La fraction alcoolique peut représenter de 5% à 99,9% et mieux de 8% à 80%. Pour une application mascara, la composition est de préférence une dispersion de cire-dans-eau ou de cire-dans-huile, une huile gélifiée ou un gel aqueux, pigmenté ou non. 30 La composition selon l'invention peut contenir également des adjuvants habituels dans le domaine cosmétique, choisis par exemple parmi les gélifiants ou épaississants hydrophiles ou lipophiles, les additifs hydrophiles ou lipophiles, les conservateurs, les antioxydants (caroténoïdes), les parfums, les charges, les absorbeurs d'odeurs, les électrolytes, les neutralisants, les agents bloqueurs d'U.V. comme 35 les filtres solaires, les polymères filmogènes, les actifs cosmétiques comme les vitamines différentes des vitamines B, leurs analogues et dérivés; les matières colorantes, solubles ou non dans le milieu. Les quantités de ces différents adjuvants sont celles classiquement utilisées dans le domaine cosmétique, par exemple de 0,01 à 20%, mieux de 0,1 à 10% du poids total de la composition. Ces 40 adjuvants, selon leur nature, peuvent être introduits dans la phase grasse, dans la phase aqueuse et/ou dans les vésicules lipidiques et notamment des liposomes. Comme huiles ou cires susceptibles d'être employées, on peut citer les huiles mi- 25 nérales (huile de vaseline, isoparaffine hydrogénée), les huiles végétales (fraction liquide du beurre de karité, huile de tournesol, de soja, de germes de blé), les huiles animales (perhydrosqualène), les huiles de synthèse (huile de Purcellin, esters d'acide gras), les huiles ou cires siliconées (polydiméthylsiloxanes linéaires ou cycliques, cyclométhicone, phényltriméthicone), les huiles fluorées (perfluoro- polyéthers), les cires d'abeille, de Candellila, de riz, de carnauba, de paraffine ou de polyéthylène. On peut également citer des alcools gras et des acides gras (acide stéarique, linoléique, linolénique par exemple).Preferably, the composition according to the invention comprises the vitamin B or vitamin or analogues or derivatives in an amount of between 0.001 and 5% by weight, in particular 0.005 and 2% by weight, and more preferably between 0.01 and 1% by weight. , relative to the total weight of the composition. 3. Additional Ingredients The composition according to the invention may be for cosmetic or pharmaceutical use. Preferably, the composition according to the invention is for cosmetic use. By "cosmetic" is meant in the sense of the invention a composition of appearance, smell and pleasant touch. Preferably, the composition is applied topically to the skin and the keratinous fibers, and more particularly to the hairy leather, the hair and the eyelashes. Depending on the mode of application, this composition may be in any galenical form normally used in the field in question, in particular cosmetics. For topical application to the skin, including the scalp, the composition may be in the form of an aqueous, alcoholic or aqueous-alcoholic solution or suspension, a suspension or an oily solution, an emulsion 40 or dispersion of liquid or semi-liquid consistency obtained by dispersion of a fatty phase in an aqueous phase (HIE) or vice versa (W / O), a dispersion or emulsion of soft consistency, an aqueous or hydroalcoholic or oily gel (anhydrous), a free or compacted powder to be used as such or to incorporate in a physiologically acceptable medium (excipient), or microcapsules or microparticles, or vesicular dispersions of ionic and / or nonionic type. It is also possible to envisage a composition in the form of a foam or in the form of an aerosol composition also comprising a propellant under pressure. In particular, the composition according to the invention may be a hair composition, capable of being applied to the scalp or the hair, and may be in the form of a hair care lotion, for example of application daily or biweekly, a shampoo or a hair conditioner, particularly for biweekly or weekly application, a liquid soap or solid daily application scalp cleansing, a product implementation form of the hairstyle (lacquer, product for styling, styling gel), a mask, a cream or a foaming gel for cleaning the hair. It can still be in the form of hair dye or mascara to be applied by brush or comb. For an application on eyelashes or bristles, the composition according to the invention may be in the form of a mascara, pigmented or not, to be applied to the brush 20 on the eyelashes or on the beard or mustache hairs. According to a particular embodiment, the composition according to the invention is in the form of a hair cream or lotion, a shampoo, a hair conditioner, or a hair or eyelash mascara. The amounts of the various constituents of the composition according to the invention are those conventionally used in the fields under consideration. In addition, this composition is prepared according to the usual methods. It can thus be in the form of a lotion, serum, milk, O / W cream or W / O, gel, ointment, ointment, powder, balm, patch, soaked pad, soap, bread, mousse. When the composition is an emulsion, the proportion of the fatty phase may range from 2 to 80% by weight, preferably from 5 to 50% by weight relative to the total weight of the composition. The fatty phase may contain fatty or oily compounds which are liquid at room temperature (25 ° C.) and atmospheric pressure (1 atm), generally called oils. These oils may or may not be compatible with each other and form a macroscopically homogeneous liquid fatty phase or a two- or three-phase system. The fatty phase may, in addition to the oils, contain waxes, gums, lipophilic polymers, "pasty" or viscous products containing solid parts and liquid parts. The aqueous phase is adjusted according to the fatty phase content and compound (s) of formula (I) and that of any additional ingredients, to obtain 100% by weight. In practice, the aqueous phase is preferably 5 to 99.9% by weight. The aqueous phase contains water and optionally an organic solvent which is used in all proportions with water, such as lower C1 to C8 alcohols such as ethanol, isopropanol, polyols such as propylene glycol and glycerol. , sorbitol or acetone. The emulsifiers and coemulsifiers used in the composition in emulsion form may be chosen from those conventionally used in the cosmetics or pharmaceutical field. The emulsifier and / or the coemulsifier are preferably present in the composition in a proportion ranging from 0.1 to 30% by weight, preferably from 0.5 to 20% by weight relative to the total weight of the composition, better from 1 to 8%. Their nature is, moreover, a function of the meaning of the emulsion. The emulsion may further comprise lipid vesicles and especially liposomes. When the composition is a solution or an oily gel, the fatty phase may represent more than 90% of the total weight of the composition. Advantageously, for a capillary application, the composition is an aqueous, alcoholic or aqueous-alcoholic solution or suspension, and better a solution or a water / ethanol suspension. The alcoholic fraction can represent from 5% to 99.9% and better still from 8% to 80%. For a mascara application, the composition is preferably a wax-in-water or wax-in-oil dispersion, a gelled oil or an aqueous gel, pigmented or not. The composition according to the invention may also contain adjuvants customary in the cosmetic field, chosen, for example, from hydrophilic or lipophilic gelling agents or thickeners, hydrophilic or lipophilic additives, preservatives, antioxidants (carotenoids), perfumes, fillers. , odor absorbers, electrolytes, neutralizers, UV blocking agents such as sunscreens, film-forming polymers, cosmetic actives such as vitamins other than B vitamins, their analogues and derivatives; dyestuffs, soluble or not in the medium. The amounts of these various adjuvants are those conventionally used in the cosmetics field, for example from 0.01 to 20%, better still from 0.1 to 10% of the total weight of the composition. These adjuvants, depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into the lipid vesicles and in particular liposomes. As oils or waxes that may be employed, mention may be made of mineral oils (liquid petroleum jelly, hydrogenated isoparaffin), vegetable oils (liquid fraction of shea butter, sunflower oil, soya bean oil, wheat germ oil). ), animal oils (perhydrosqualene), synthetic oils (Purcellin oil, fatty acid esters), silicone oils or waxes (linear or cyclic polydimethylsiloxanes, cyclomethicone, phenyltrimethicone), fluorinated oils (perfluoropolyethers), beeswax, Candelilla wax, rice wax, carnauba wax, paraffin wax or polyethylene wax. Mention may also be made of fatty alcohols and fatty acids (stearic acid, linoleic acid, linolenic acid for example).
Comme émulsionnants utilisables dans l'invention, on peut citer par exemple les alcools gras oxyéthylénés, le stéarate ou laurate de glycérol, le stéarate ou oléate de sorbitol polyoxyéthyléné (par exemple le polysorbate 60 et le mélange de PEG6/PEG-32/Glycol Stéarate vendu sous la dénomination de Tefose® 63 par la société Gattefosse), les (alkyl)diméthicones copolyol.As emulsifiers that can be used in the invention, mention may be made, for example, of oxyethylenated fatty alcohols, glycerol laurate or stearate, polyoxyethylenated sorbitol stearate or oleate (for example polysorbate 60 and the PEG6 / PEG-32 / glycol stearate mixture). sold under the name Tefose® 63 by the company Gattefosse), (alkyl) dimethicones copolyol.
Comme gélifiants hydrophiles utilisables dans l'invention, on peut citer les polymères carboxyvinyliques (carbomer), les copolymères acryliques tels que les copolymères d'acrylates/alkylacrylates, les polyacrylam ides, les polysaccharides tels que l'hydroxypropylcellulose, les gommes naturelles et les argiles, et, comme géli- fiants lipophiles, on peut citer les argiles modifiées comme les Bentones, les sels métalliques d'acides gras comme les stéarates d'aluminium, la silice traitée hydrophobe, l'éthylcellulose et leurs mélanges. La composition peut comprendre d'autres actifs qui peuvent être hydrophiles, comme les protéines ou les hydrolysats de protéine, les acides aminés, les po- lyols, l'urée, l'allantoïne, les sucres et les dérivés de sucre, les vitamines hydrosolubles, les extraits végétaux, ces extraits pouvant alors contenir ou non des isoflavones; ou qui peuvent être lipophiles, comme le rétinol (vitamine A) et ses dérivés notamment ester (palmitate), le tocophérol (vitamine E) et ses dérivés, notamment ester (acétate palmitate), les acides gras essentiels comme les acides eicosaté- traénoïque et eicosatriénoïque ou leurs esters et amides, les céram ides, les huiles essentielles, les esters des hydroxyacides, les phospholipides comme la lécithine; ou qui peuvent être solubles dans des solvants alcooliques comme les lactones (kawaïne); et leurs mélanges.As hydrophilic gelling agents that may be used in the invention, mention may be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate / alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural gums and clays. and, as lipophilic gelling agents, are modified clays such as Bentones, metal salts of fatty acids such as aluminum stearates, hydrophobically treated silica, ethylcellulose and mixtures thereof. The composition may comprise other actives that may be hydrophilic, such as proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins plant extracts, these extracts may then contain or not isoflavones; or which may be lipophilic, such as retinol (vitamin A) and its derivatives in particular ester (palmitate), tocopherol (vitamin E) and its derivatives, in particular ester (acetate palmitate), essential fatty acids such as eicosatetraenoic acids and eicosatrienoic or their esters and amides, ceramides, essential oils, esters of hydroxy acids, phospholipids such as lecithin; or which may be soluble in alcoholic solvents such as lactones (kawaïne); and their mixtures.
La composition peut notamment comprendre des actifs additionnels favorisant en particulier la repousse des fibres kératiniques humaines et/ou limitant leur chute, notamment choisis parmi : - les hormones en particulier d'origine végétale par exemple l'estriol ou ses ana- logues, la thyroxine et ses sels, la progestérone ; - les agents antibactériens tels que les macrolides, les pyranosides et les tétracyclines, et notamment l'érythromycine ; - les agents antagonistes de calcium, comme la cinnarizine, le diltiazem, la nimo- dipine, le vérapamil et la nifédipine ; - les extraits de micro-organismes notamment les extraits bactériens ; - les agents modulant la différenciation et/ou la prolifération cutanée tels que l'acide rétindique et ses isomères, le rétinol et ses esters, la vitamine D et ses dé- rivés, les oestrogènes tels que rcestradiol ; - les agents modulant l'adhésion bactérienne sur la peau et /ou les muqueuses tels que le miel, notamment le miel d'acacias et certains dérivés de sucres ; - les antiparasitaires, en particulier le métronidazole, le crotamiton ou les pyréthrinoïdes ; - les antifongiques, en particulier les composés appartenant à la classe des imi- dazoles tels que l'éconazole, le kétoconazole ou le miconazole ou leurs sels, les esters d'acide nicotinique dont notamment le nicotinate de tocophérol, le nicotinate de benzyle et les nicotinates d'alkyles en C1-C6 comme les nicotinates de méthyle ou d'hexyle ; les composés polyènes, tels que l'amphotéricine B, les composés de la famille des allylamines, tels que la terbinafine, ou encore l'octopirox, les dérivés du sélénium ou l'anthraline ; - les agents antiviraux tels que l'acyclovir ; - les agents anti-inflammatoires stéroïdiens tels que les corticostéroïdiens comme l'hydrocortisone, le valérate de bétaméthasone ou le propionate de clobé- tasol, ou les agents anti-inflammatoires non-stéroïdiens tels que l'ibuprofène et ses sels, le diclofénac et ses sels, l'acide acétylsalicylique, l'acétaminophène ou l'acide glycyrrhétinique, l'a-bisabolol ; - les agents anesthésiques tels que le chlorhydrate de lidocaïne et ses dérivés ; - les agents antiprurigineux comme la thénaldine, la triméprazine ou la cyprohep- tadine ; - les agents kératolytiques tels que les acides alpha- et bêtahydroxycarboxyliques ou bêta-cétocarboxyliques, leurs sels, amides ou esters, les lactones et leurs sels correspondants, et plus particulièrement les hydroxy-acides tels que l'acide glycolique, l'acide lactique, l'acide salicylique, l'acide citrique et de manière générale les acides de fruits, les dérivés de l'acide salicylique tels que ceux porteurs d'un radical alcanoyle ayant de 2 à 12 atomes de carbone en position 5 du cycle benzénique comme l'acide n-octanoy1-5-salicylique ; - les agents anti-radicaux libres tels que l'alpha-tocophérol ou ses esters, les su-peroxyde dismutases, certains chélatants de métaux ou l'acide ascorbique et ses 35 esters - les anti-séborrhéiques tels que la progestérone ; - les antipelliculaires comme l'octopirox ou la pyrithione de zinc ; - les antiacnéiques comme l'acide rétinoïque ou le peroxyde de benzoyle ; - les vasodilatateurs comme les dérivés de pyrimidine, comme le 2,4-diamino 6- 40 pipéridinopyrimidine 3-oxyde ou "minoxidil" décrit dans les brevets US4139619 et US4596812, le diazoxide ; - les agents diminuant la chute des cheveux comme l'aminexil, le 6-0-[(9Z,12Z)- octadéca-9,12-diènoyl]hexapyranose ; - les agents antiandrogènes tels que l'oxendolone, la spironolactone, le diéthylstilbestrol et la flutamide ; - les inhibiteurs stéroïdiens ou non stéroïdiens des 5-a-réductases tels que le finastéride ; - les agonistes potassiques tels que la cromakalim et le nicorandil ; - les agonistes du récepteur FP (récepteur aux prostaglandines de type F) tels que le latanoprost, le bimatoprost, le travoprost, l'unoprostone ; - leurs mélanges.The composition may in particular comprise additional active agents that promote, in particular, the regrowth of human keratin fibers and / or limit their fall, in particular chosen from: hormones, in particular of plant origin, for example estriol or its analogs, thyroxine and its salts, progesterone; antibacterial agents such as macrolides, pyranosides and tetracyclines, and in particular erythromycin; calcium antagonists, such as cinnarizine, diltiazem, nimo-dipine, verapamil and nifedipine; extracts of microorganisms, especially bacterial extracts; agents that modulate skin differentiation and / or proliferation such as retindic acid and its isomers, retinol and its esters, vitamin D and its derivatives, estrogens such as rcestradiol; agents that modulate bacterial adhesion to the skin and / or mucous membranes such as honey, especially acacia honey and certain sugar derivatives; antiparasitics, in particular metronidazole, crotamiton or pyrethrinoids; antifungals, in particular compounds belonging to the imidazoles class such as econazole, ketoconazole or miconazole or their salts, nicotinic acid esters including, in particular, tocopherol nicotinate, benzyl nicotinate and C1-C6 alkyl nicotinates such as methyl or hexyl nicotinates; polyene compounds, such as amphotericin B, compounds of the allylamine family, such as terbinafine, or octopirox, selenium derivatives or anthralin; antiviral agents such as acyclovir; steroidal anti-inflammatory agents such as corticosteroids such as hydrocortisone, betamethasone valerate or clobestol propionate, or non-steroidal anti-inflammatory agents such as ibuprofen and its salts, diclofenac and its derivatives; salts, acetylsalicylic acid, acetaminophen or glycyrrhetinic acid, a-bisabolol; anesthetic agents such as lidocaine hydrochloride and its derivatives; antipruritic agents such as thenaldine, trimeprazine or cyproheptadine; keratolytic agents such as alpha- and betahydroxycarboxylic acids or beta-ketocarboxylic acids, their salts, amides or esters, lactones and their corresponding salts, and more particularly hydroxy acids such as glycolic acid, lactic acid, salicylic acid, citric acid and, in general, fruit acids, salicylic acid derivatives such as those bearing an alkanoyl radical having from 2 to 12 carbon atoms at the 5-position of the benzene ring, for example n-octanoyl-5-salicylic acid; anti-free radical agents such as alpha-tocopherol or its esters, su-peroxide dismutases, certain metal chelating agents or ascorbic acid and its esters - anti-seborrheic agents such as progesterone; anti-dandruff such as octopirox or zinc pyrithione; anti-acne drugs such as retinoic acid or benzoyl peroxide; vasodilators such as pyrimidine derivatives, such as 2,4-diamino-6-piperidinopyrimidine 3-oxide or "minoxidil" described in patents US4139619 and US4596812, diazoxide; hair loss reducing agents such as aminexil, 6-0 - [(9Z, 12Z) -octadeca-9,12-dienoyl] hexapyranose; antiandrogenic agents such as oxendolone, spironolactone, diethylstilbestrol and flutamide; steroidal or nonsteroidal inhibitors of 5-a-reductases such as finasteride; potassic agonists such as cromakalim and nicorandil; agonists of the FP receptor (F-type prostaglandin receptor) such as latanoprost, bimatoprost, travoprost, unoprostone; - their mixtures.
La composition selon l'invention peut en outre comprendre des substances telles que les antagonistes de substance P, de CGRP ou de bradykinine et les inhibiteurs de NO-synthase, composés décrits comme étant actifs dans le traitement des peaux sensibles et comme présentant des effets anti-irritants, en particulier vis-à-vis de composés irritants éventuellement présents dans les compositions.The composition according to the invention may further comprise substances such as substance P, CGRP or bradykinin antagonists and NO-synthase inhibitors, compounds described as being active in the treatment of sensitive skin and having anti-inflammatory effects. irritants, in particular vis-à-vis irritating compounds possibly present in the compositions.
La composition selon l'invention, en particulier cosmétique, peut être appliquée sur les zones alopéciques du cuir chevelu et des cheveux, éventuellement laissée en contact plusieurs heures et/ou éventuellement rincée. On peut, par exemple, appliquer la composition selon l'invention le soir, garder celle-ci en contact toute la nuit et éventuellement effectuer un shampooing le ma- tin. Ces applications peuvent être renouvelées quotidiennement pendant un ou plusieurs mois suivant les individus. La présente invention a également pour objet un procédé de traitement cosmé- tique des matières kératiniques humaines, notamment des cheveux et/ou de la peau, y compris le cuir chevelu, dans lequel on applique sur lesdites matières kératiniques une composition cosmétique telle que définie ci-dessus, et éventuellement à rincer lesdites matières kératiniques. Plus spécialement, ledit procédé est un procédé de soin cosmétique des cheveux et/ou du cuir chevelu, en vue d'améliorer leur état et/ou leur aspect. Ce procédé de traitement présente bien les caractéristiques d'un procédé cosmétique dans la mesure où il permet d'améliorer l'esthétique des matières, notamment des fibres, kératiniques humaines en leur donnant une plus grande vigueur, un aspect amélioré et une plus grande facilité de coiffage. L'invention est décrite plus en détail dans les exemples suivants. Exemple 1 On prépare la composition suivante (`)/0 en poids): - diéthyl ester d'acide pyridine-2,4-dicarboxylique (nom INCI : DIETHYLLUTIDINATE) 5% - éthanol 56,5% - vitamine B3 0,02% - acide citrique qs pH = 5,5 - eau qsp 100°A Cette lotion est limpide et stable dans le temps (au moins 2 mois, à 25°C ou 5 45°C). Appliquée raie par raie sur le cuir chevelu, cette lotion présente de bonnes qualités d'usage en favorisant la distribution et la répartition des actifs sur le cuir chevelu. Elle présente également de bonnes performances cosmétiques. Les cheveux sont soyeux et légers, la chevelure est disciplinée et facile à coiffer.The composition according to the invention, in particular cosmetic, can be applied to the alopecic areas of the scalp and hair, possibly left in contact for several hours and / or possibly rinsed. For example, it is possible to apply the composition according to the invention in the evening, keep it in contact all night long and possibly shampoo the morning. These applications can be renewed daily for one or more months depending on the individual. The present invention also relates to a process for the cosmetic treatment of human keratin materials, in particular the hair and / or the skin, including the scalp, in which a cosmetic composition as defined herein is applied to said keratin materials. above, and possibly rinsing said keratin materials. More particularly, said method is a method of cosmetic care of the hair and / or the scalp, with a view to improving their state and / or their appearance. This treatment method has the characteristics of a cosmetic process insofar as it makes it possible to improve the aesthetics of materials, especially human keratin fibers, by giving them greater vigor, an improved appearance and greater ease. styling. The invention is described in more detail in the following examples. Example 1 The following composition is prepared (`) / 0 by weight): - pyridine-2,4-dicarboxylic acid diethyl ester (INCI name: DIETHYLLUTIDINATE) 5% - ethanol 56.5% - vitamin B3 0.02% citric acid qs pH = 5.5 - water qs 100 ° C. This lotion is clear and stable over time (at least 2 months at 25 ° C. or 45 ° C.). Applied line by line on the scalp, this lotion has good qualities of use by promoting the distribution and distribution of active ingredients on the scalp. It also has good cosmetic performance. The hair is silky and light, the hair is disciplined and easy to comb.
10 Exemple 2 On prépare la composition suivante (`)/0 en poids): - diéthyl ester d'acide pyridine-2,4-dicarboxylique (nom INCI : DIETHYLLUTIDINATE) 5% 15 - éthanol 56,5% - vitamine B3 0,01% - pantothénate de calcium 0,01% - acide citrique qs pH = 5,5 - eau qsp 100°A 20 Cette lotion est limpide et stable dans le temps (au moins 2 mois, à 25°C ou 45°C). Appliquée raie par raie sur le cuir chevelu, cette lotion présente de bonnes qualités d'usage en favorisant la distribution et la répartition des actifs sur le cuir cheve25 lu. Elle présente également de bonnes performances cosmétiques. Les cheveux sont soyeux et légers, la chevelure est disciplinée et facile à coiffer.EXAMPLE 2 The following composition is prepared (`) / 0 by weight): - pyridine-2,4-dicarboxylic acid diethyl ester (INCI name: DIETHYLLUTIDINATE) 5% 15 - ethanol 56.5% - vitamin B3 0, 01% - calcium pantothenate 0.01% - citric acid qs pH = 5.5 - water qs 100 ° A 20 This lotion is clear and stable over time (at least 2 months at 25 ° C or 45 ° C) . Applied line by line on the scalp, this lotion has good qualities of use by promoting the distribution and distribution of assets on the leather cheve25 read. It also has good cosmetic performance. The hair is silky and light, the hair is disciplined and easy to comb.
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1255610A FR2991874B1 (en) | 2012-06-15 | 2012-06-15 | COMPOSITION COMPRISING A DYARBOXYLIC PYRIDINE ACID ESTER AND A VITAMIN B, A METHOD AND USE |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1255610A FR2991874B1 (en) | 2012-06-15 | 2012-06-15 | COMPOSITION COMPRISING A DYARBOXYLIC PYRIDINE ACID ESTER AND A VITAMIN B, A METHOD AND USE |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2991874A1 true FR2991874A1 (en) | 2013-12-20 |
FR2991874B1 FR2991874B1 (en) | 2014-08-29 |
Family
ID=46785651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1255610A Expired - Fee Related FR2991874B1 (en) | 2012-06-15 | 2012-06-15 | COMPOSITION COMPRISING A DYARBOXYLIC PYRIDINE ACID ESTER AND A VITAMIN B, A METHOD AND USE |
Country Status (1)
Country | Link |
---|---|
FR (1) | FR2991874B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3021214A1 (en) * | 2014-05-20 | 2015-11-27 | Oreal | COMPOSITION COMPRISING A DYARBOXYLIC PYRIDINE ACID ESTER, A SURFACTANT AND A LIQUID MONOALCOOL, PROCESS AND USE |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990012560A2 (en) * | 1989-04-20 | 1990-11-01 | Stueckler Erwin | Preparation for care of nails, skin and hair |
DE4401274A1 (en) * | 1994-01-18 | 1995-07-20 | Rooyan Behdasht Co | Liq. agent for promoting and maintaining hair growth |
DE29812754U1 (en) * | 1998-07-17 | 1998-12-24 | Keudel Alvermann, Irmela von, 49377 Vechta | Hair restorer |
EP1352629A1 (en) * | 2002-04-11 | 2003-10-15 | L'oreal | Use of a pyridine-dicarboxylic acid derivative or a salt thereof to stimulate or induce keratinic fiber growth and/or to prevent its loss |
DE202008005504U1 (en) * | 2008-04-21 | 2008-07-03 | Burkert, Dagmar | Hair restorer for men |
-
2012
- 2012-06-15 FR FR1255610A patent/FR2991874B1/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990012560A2 (en) * | 1989-04-20 | 1990-11-01 | Stueckler Erwin | Preparation for care of nails, skin and hair |
DE4401274A1 (en) * | 1994-01-18 | 1995-07-20 | Rooyan Behdasht Co | Liq. agent for promoting and maintaining hair growth |
DE29812754U1 (en) * | 1998-07-17 | 1998-12-24 | Keudel Alvermann, Irmela von, 49377 Vechta | Hair restorer |
EP1352629A1 (en) * | 2002-04-11 | 2003-10-15 | L'oreal | Use of a pyridine-dicarboxylic acid derivative or a salt thereof to stimulate or induce keratinic fiber growth and/or to prevent its loss |
DE202008005504U1 (en) * | 2008-04-21 | 2008-07-03 | Burkert, Dagmar | Hair restorer for men |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3021214A1 (en) * | 2014-05-20 | 2015-11-27 | Oreal | COMPOSITION COMPRISING A DYARBOXYLIC PYRIDINE ACID ESTER, A SURFACTANT AND A LIQUID MONOALCOOL, PROCESS AND USE |
Also Published As
Publication number | Publication date |
---|---|
FR2991874B1 (en) | 2014-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1352629B1 (en) | Use of a pyridine-dicarboxylic acid derivative or a salt thereof to stimulate or induce keratinic fiber growth and/or to prevent its loss | |
EP1337234B1 (en) | Use of 2-oxothiazolidine 4-carboxylic acid derivatives as agents promoting skin peeling | |
EP2861206B1 (en) | Composition including a pyridine dicarboxylic acid ester and a binding polymer, method therefor, and use thereof for treating hair | |
EP1558203B1 (en) | Hair treatment composition containing a styryl-pyrazole compound | |
EP1688128B1 (en) | Method for treating keratinic fibres and the scalp with a composition containing a derivative of glucose and vitamin F | |
FR2744916A1 (en) | USE OF A 2-AMINO-ALCANE-1,3-DIOL AS AN AGENT FOR BRAKING HAIR LOSS AND / OR INDUCING AND STIMULATING THEIR GROWTH | |
EP1849456A1 (en) | Use of a 4-aminopiperidine derivative as agent for inducing and/or stimulating the growth of keratin fibres and/or preventing their loss | |
FR2816837A1 (en) | Use of amino sulfonic acid derivatives in cosmetic compositions to aid desquamation, counteract aging and stimulate epidermal renewal | |
EP2119431B1 (en) | Composition containing the combination of madecassoside and/or of terminoloside and of an arginine and/or a salt thereof and/or a derivative thereof; use of the combination for inducing and/or stimulating the growth of human keratin fibres and/or preventing their loss | |
EP2119475B1 (en) | Composition containing the combination of 2,4 diaminopyrimidine-3-n-oxide and of madecassoside and/or of terminoloside; use of the combination for inducing and/or stimulating the growth of human keratin fibres and/or preventing their loss. | |
EP2861205B1 (en) | Composition including a pyridine dicarboxylic acid ester and a glucose and fatty acid ester. | |
FR2991874A1 (en) | Composition, useful as hair cosmetic composition e.g. hair care lotion for treating human keratinous materials such as hair and/or scalp, comprises pyridine dicarboxylic acid ester, and vitamin B and/or its analogs or derivatives | |
FR2860431A1 (en) | Use of phenylazo benzene, pyridine or pyridazine derivatives as agents for inducing and/or stimulating growth of human keratinic fibers and/or inhibiting their loss and/or increasing their density | |
FR2947449A1 (en) | COSMETIC USES OF A JASMONIC ACID DERIVATIVE FOR THE NATURAL ANTIOXIDANT PROTECTION OF THE SKIN, FOR THE TREATMENT OF HAIR AND SCALP | |
EP1739083A1 (en) | Benzylidene-1,3-thiazolidine-2,4-dione compounds, uses thereof and compositions for stimulating or inducing the growth and/or for reducing the loss and/or for increasing the density of keratin fibres | |
EP1738742A2 (en) | Benzyl-1,3-thiazolidine-2,4-dione compounds, compositions comprising them and use for stimulating or inducing the growth of keratinic fibres and/or for diminsihing their loss | |
FR2764504A1 (en) | Use of a lipid-free milk product | |
FR2751965A1 (en) | NOVEL COMPOUNDS OF THE ARYL-2,4-DIOXO-OXAZOLIDINE FAMILY | |
FR2858770A1 (en) | USE OF A CARBONYLATED AMINE FOR STIMULATING THE PUSH OF KERATIN FIBERS AND / OR BRAKING THEIR FALL | |
EP1698337A1 (en) | Use of cyclic amine derivatives in capillary products | |
FR2898048A1 (en) | COSMETIC USE OF THEOPHYLLINE N-OXIDE DERIVATIVE | |
FR2925048A1 (en) | 2-FLUORO-4 - [(3,3,3-TRIFLUORO-2-HYDROXY-2-METHYPROPANOYL) AMINO] BENZOATE DERIVATIVES; USES FOR STIMULATING AND / OR INDUCING THE PUSH OF KERATIN FIBERS AND / OR BRAKING THEIR FALL; COMPOSITIONS CONTAINING THEM | |
FR2860432A1 (en) | Use of 1,3-diazacycloalkene derivatives as lysyl hydroxylase inhibitors, especially for inducing and/or stimulating growth of human keratinic fibers and/or inhibiting their loss and/or increasing their density | |
EP1849455A1 (en) | Use of a 4-aminopiperidine derivative as agent for inducing and/or stimulating the growth of keratin fibres and/or preventing their loss | |
FR2823109A1 (en) | USE OF ALVERINE OR ONE OF ITS SALTS TO STIMULATE OR INDUCE HAIR GROWTH AND / OR STOP THEIR LOSS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 5 |
|
PLFP | Fee payment |
Year of fee payment: 6 |
|
PLFP | Fee payment |
Year of fee payment: 7 |
|
ST | Notification of lapse |
Effective date: 20200206 |